LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for treatment-resistant metastatic breast cancer and ALS. Its lead candidates are lasofoxifene, a SERM in-licensed in December 2025 for ESR1-mutated metastatic breast cancer currently in a Phase 3 trial (ELAINE-3), and ATH-1105, a small-molecule HGF system modulator that completed Phase 1 and is Phase 2-ready for ALS treatment.
expected 2026-12-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134565 | EDGAR | 117K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029069 | EDGAR | 87K words |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018787 | EDGAR | 94K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009498 | EDGAR | 94K words |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004782 | EDGAR | 97K words |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015495 | EDGAR | 111K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001193125-26-352243 | EDGAR | 74K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269544 | EDGAR | 67K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105052 | EDGAR | 66K words |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068040 | EDGAR | 64K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123372 | EDGAR | 72K words |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089304 | EDGAR | 70K words |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060482 | EDGAR | 67K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062082 | EDGAR | 70K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041346 | EDGAR | 70K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021274 | EDGAR | 68K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024499 | EDGAR | 68K words |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017421 | EDGAR | 67K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-22 | 0001193125-26-397952 | EDGAR | 1K words |
| 2026-08-26 | 0001193125-26-368288 | EDGAR | 1K words |
| 2026-08-14 | 0001193125-26-352208 | EDGAR | 3K words |
| 2026-03-26 | 0001193125-26-126579 | EDGAR | 3K words |
| 2026-03-19 | 0001193125-26-116123 | EDGAR | 11K words |
| 2026-01-09 | 0001193125-26-008904 | EDGAR | 2K words |
| 2025-12-18 | 0001193125-25-323692 | EDGAR | 47K words |
| 2025-11-06 | 0001193125-25-269506 | EDGAR | 2K words |
| 2025-10-03 | 0001193125-25-229293 | EDGAR | 1K words |
| 2025-09-11 | 0000950170-25-114093 | EDGAR | 1K words |
97 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001620463 |
| Ticker | LONA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.leonabio.com |
| Listed | 2020-09-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LONA (~200 tokens, structured JSON with cryptographic provenance)